Oshima Shinichiro, Arai Yasuyuki, Kondo Tadakazu, Yano Shingo, Hirabayashi Shigeki, Uchida Naoyuki, Onizuka Makoto, Miyakoshi Shigesaburo, Tanaka Masatsugu, Takahashi Satoshi, Hayashi Masayuki, Kawakita Toshiro, Uehara Yasufumi, Ota Shuichi, Izumi Toru, Sawa Masashi, Nishida Tetsuya, Katayama Yuta, Nagafuji Koji, Kato Koji, Ichinohe Tatsuo, Atsuta Yoshiko, Yanada Masamitsu
Department of Hematology, Kyoto University Hospital, Kyoto, Japan.
Division of Clinical Oncology Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Bone Marrow Transplant. 2025 Apr;60(4):458-466. doi: 10.1038/s41409-025-02508-2. Epub 2025 Jan 21.
Umbilical cord blood transplantation (CBT) is accepted as an effective treatment for acute myeloid leukemia (AML), and reduced-intensity conditioning (RIC), rather than myeloablative conditioning (MAC) regimens allowed elderly patients to be treated safely. However, appropriate intensities of conditioning regimens are still unclear, especially for middle-aged patients. To compare outcomes after RIC and MAC regimens, we analyzed AML patients aged 16 years or older in the Japanese registry database, who underwent single cord unit CBT between 2010-2019. Median ages of the RIC group (n = 1353) and the MAC group (n = 2101) were 59 and 51 years (P < 0.001), respectively. 5-year overall survival (OS) after MAC was superior to that of RIC (38.3% vs 27.7%, P < 0.001) with lower incidence of relapse (33.9% vs 37.4%, P = 0.029) and better neutrophil engraftment (84.7% vs 75.9%, P < 0.001). Detailed subgroup analysis revealed that age at transplantation is the most important factor affecting 5-year OS in RIC and MAC. This analysis identified a threshold of 55 years, beyond which the superiority of MAC disappeared, irrespective of other factors such as disease status or performance status. In conclusion, RIC may be preferable for patients aged 56 or older in CBT for AML due to higher potential toxicities.
脐带血移植(CBT)被公认为是治疗急性髓系白血病(AML)的一种有效方法,与清髓性预处理(MAC)方案相比,降低强度预处理(RIC)方案能使老年患者得到安全治疗。然而,预处理方案的合适强度仍不明确,尤其是对于中年患者。为了比较RIC和MAC方案后的疗效,我们分析了日本登记数据库中2010年至2019年间接受单份脐带血单位CBT的16岁及以上AML患者。RIC组(n = 1353)和MAC组(n = 2101)的中位年龄分别为59岁和51岁(P < 0.001)。MAC方案后的5年总生存率(OS)优于RIC方案(38.3%对27.7%,P < 0.001),复发率更低(33.9%对37.4%,P = 0.029),中性粒细胞植入情况更好(84.7%对75.9%,P < 0.001)。详细的亚组分析显示,移植时的年龄是影响RIC和MAC方案5年总生存率的最重要因素。该分析确定了55岁的阈值,超过该阈值,MAC方案的优势消失,无论疾病状态或体能状态等其他因素如何。总之由于潜在毒性较高,对于56岁及以上的AML患者进行CBT时,RIC方案可能更可取。